News from heptares therapeutics A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jul 07, 2014, 04:00 ET

Heptares Announces Publication in Nature of First Structure of Metabotropic Glutamate Receptor 5 Transmembrane Domain

Heptares has solved structures across all major GPCR families (A, B and C) providing platforms for wide-ranging structure-based and antibody drug...

Jun 30, 2014, 04:00 ET

Heptares' Chief Scientific Officer and Co-Founder Fiona Marshall to Present at Royal Society of Medicine Medical Innovations Summit

Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, is delighted to announce that Fiona Marshall,...

Jun 24, 2014, 13:00 ET

Heptares to Present at JMP Securities Healthcare Conference

Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, announces that its President, Dan Grau, will...

May 29, 2014, 04:00 ET

Heptares to Present at Jefferies 2014 Global Healthcare Conference and Upcoming Industry and Scientific Events

Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, notes that Malcolm Weir, Heptares' Chief...

May 15, 2014, 04:00 ET

Heptares to Present at UBS Global Healthcare Conference and Upcoming Scientific Events

Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, notes that Fiona Marshall, Heptares' Chief...

Apr 16, 2014, 04:00 ET

Heptares at Upcoming Diabetes and Neuroscience Partnering and Investment Conferences

Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, notes that Dan Grau, Heptares' President, will be...

Mar 26, 2014, 05:00 ET

Heptares Presentation at Future Leaders in the Biotech Industry to be Webcast

Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, notes that a company presentation to be given by...

Mar 07, 2014, 06:15 ET

Heptares to Present at Upcoming Biotech Business Development Events

Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, notes that its Chief Executive Officer, Malcolm...

Jan 23, 2014, 04:00 ET

Heptares Successfully Completes Research Phase of Antibody Discovery Collaboration with MedImmune

Stabilised GPCR (StaR®) Proteins Delivered For All Nominated Targets Heptares Therapeutics, the leading GPCR structure-guided drug discovery...

Jan 09, 2014, 04:00 ET

Heptares Appoints Tim Tasker as Chief Medical Officer

Increases Focus on Clinical Development of Novel GPCR-targeted Drug Candidates Heptares Therapeutics, the leading GPCR structure-guided drug...

Jan 08, 2014, 04:00 ET

Heptares to Moderate Panel on Global Business Development at Upcoming Boston Biotech East/West CEO Conference

Heptares Therapeutics, the leading GPCR drug discovery and development company, notes that its President, Dan Grau, will moderate a panel...

Dec 16, 2013, 04:00 ET

Heptares Highlights Potential of StaR® Proteins as Antigens for GPCR-Targeted Antibody Discovery in New Scientific Publication

Biased Agonist Antibodies Generated To G Protein-Coupled Receptor Heptares Therapeutics, the leading GPCR structure-guided drug discovery and...

Dec 09, 2013, 03:00 ET

Heptares Initiates Clinical Study With First Selective Muscarinic M1 Receptor Agonist for Improving Cognition in Patients With Alzheimer's Disease

First Human Trial of Novel Small Molecule Drug Derived From Heptares GPCR-Focused Structure-Based Drug Design Platform Heptares Therapeutics, the...

Oct 31, 2013, 05:00 ET

Heptares to Present at Upcoming Scientific and Biotech Industry Conferences

Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, notes that members of its senior management team...

Oct 10, 2013, 04:00 ET

Heptares Delivers First Stabilised GPCR (StaR®) to MorphoSys for Antibody Discovery

Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, achieved the first research milestone in its...

Sep 06, 2013, 05:43 ET

Heptares to Present at Upcoming Scientific and Biotech Industry Conferences

Heptares Therapeutics, the leading GPCR drug discovery and development company, notes that it will be presenting at the following scientific...

Jul 22, 2013, 03:00 ET

Heptares Achieves First Research Milestone in Research Collaboration with Cubist

StaR® Generated to Important GPCR Target Selected by Cubist Heptares Therapeutics, the leading GPCR drug discovery and development company,...

Jul 17, 2013, 13:05 ET

Heptares Announces Publication in Nature of Class B GPCR Structure

Unique structural insights from CRF1 structure will drive drug discovery programmes targeting important Class B GPCRs including GLP1...

Jun 27, 2013, 03:00 ET

Heptares Raises US$21 Million to Advance Novel GPCR Medicines into Clinical Development

Initial focus on neuroscience with first-in-class drugs for Alzheimer's disease and schizophrenia Heptares Therapeutics, the leading GPCR drug...

Jun 06, 2013, 04:00 ET

Heptares to Present at Upcoming Biotech Industry Conferences

Heptares Therapeutics, the leading GPCR drug discovery company, notes that it will be presenting at the following biotech industry events over the...